Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.

Journal Article (Journal Article)

BACKGROUND: Post-transplant lymphoproliferative disorders (PTLD) are associated with significant morbidity and mortality following allogeneic hematopoietic cell transplant (alloHCT). Although most PTLD is EBV-positive (EBVpos ), EBV-negative (EBVneg ) PTLD is reported, yet its incidence and clinical impact remain largely undefined. Furthermore, factors at the time of transplant impacting survival following PTLD are not well described. METHODS: Between 2002 and 2014, 432 cases of PTLD following alloHCT were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). After exclusions, 267 cases (EBVpos  = 222, 83%; EBVneg  = 45, 17%) were analyzed. RESULTS: Two hundred and eight patients (78%) received in vivo T-cell depletion (TCD) with either anti-thymocyte globulin (ATG) or alemtuzumab. Incidence of PTLD was highest using umbilical cord donors (UCB, 1.60%) and lowest using matched related donors (MRD, 0.40%). Clinical features and histology did not significantly differ among EBVpos or EBVneg PTLD cases except that absolute lymphocyte count recovery was slower, and CMV reactivation was later in EBVneg PTLD [EBVpos 32 (5-95) days versus EBVneg 47 (10-70) days, P = .016]. There was no impact on survival by EBV status in multivariable analysis [EBVneg RR 1.42, 95% CI 0.94-2.15, P = .097]. CONCLUSIONS: There is no difference in survival outcomes for patients with EBVpos or EBVneg PTLD occurring following alloHCT and 1-year survival is poor. Features of conditioning and use of serotherapy remain important.

Full Text

Duke Authors

Cited Authors

  • Naik, S; Riches, M; Hari, P; Kim, S; Chen, M; Bachier, C; Shaughnessy, P; Hill, J; Ljungman, P; Battiwalla, M; Chhabra, S; Daly, A; Storek, J; Ustun, C; Diaz, MA; Cerny, J; Beitinjaneh, A; Yared, J; Brown, V; Page, K; Dahi, PB; Ganguly, S; Seo, S; Chao, N; Freytes, CO; Saad, A; Savani, BN; Woo Ahn, K; Boeckh, M; Heslop, HE; Lazarus, HM; Auletta, JJ; Kamble, RT

Published Date

  • October 2019

Published In

Volume / Issue

  • 21 / 5

Start / End Page

  • e13145 -

PubMed ID

  • 31301099

Pubmed Central ID

  • PMC7239317

Electronic International Standard Serial Number (EISSN)

  • 1399-3062

Digital Object Identifier (DOI)

  • 10.1111/tid.13145


  • eng

Conference Location

  • Denmark